Day 181 Generic Drug Launch: The Definitive Analyst’s Guide to Identifying, Timing, and Winning Generic Entry Opportunities
The global generic drugs market was valued at $468.08 billion in 2025 and is projected to reach $728.64 billion by […]
Cancer Drug ROI: Why Pharma Makes $14.50 for Every $1 Spent on R&D
An evidence-based analysis of FDA-approved oncology drug economics, patent strategy, and what the numbers actually mean for payers, investors, and
Cancer Drug ROI: Why Pharma Makes $14.50 for Every $1 Spent on R&D Read Post »
What the Most Successful Drug Launches Reveal About Modern Pharma IP, Pricing, and Market Strategy
Recent successful drug launches indicate a trend toward more specialized, high-priced drugs that treat less-common medical conditions.
US Drug Spending: Where $603 Billion Goes, How IP Architecture Shapes Every Dollar, and What It Means for Pharma Investors
Prescription drugs are expensive to develop, and many intermediaries stand between patients and drug makers. Here’s where the money goes.
Orphan Drug Reform: How Mark Cuban’s Cost-Plus Model Is Forcing a Reckoning
1. Why This Matters Now Rare disease drugs now account for 52% of all new molecular entities (NMEs) approved by
Orphan Drug Reform: How Mark Cuban’s Cost-Plus Model Is Forcing a Reckoning Read Post »
How AI Is Irrevocably Altering the DNA of Drug Development
A Comprehensive Industry Report regarding the Technological, Economic, and Regulatory Transformation of the Pharmaceutical Sector (2025-2030) Executive Summary: The End
How AI Is Irrevocably Altering the DNA of Drug Development Read Post »
Drug Patent Searching: The Definitive Intelligence Guide for Pharma Teams
For IP counsel, portfolio managers, R&D leads, and institutional investors who need to move faster than the competition. Why Drug
Drug Patent Searching: The Definitive Intelligence Guide for Pharma Teams Read Post »
Drug Repositioning: The Definitive Guide to Rescuing Shelved Assets for Rare, Orphan, and Neglected Diseases
1. The R&D Productivity Crisis: What the Numbers Actually Say The pharmaceutical industry’s core operating model has a compounding cost
PBMs, Formularies, and Rebates: What Investors Should Know
Deconstructing the Middleman: Beyond the Textbook Definition To truly grasp the PBM’s role, we must look past the simple definition
PBMs, Formularies, and Rebates: What Investors Should Know Read Post »
